Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Momotaro-Gene

Request full access

Biotherapeutics company advancing gene therapies for cancer treatment with a focus on relapsed malignant pleural mesothelioma

Okayama, JapanFounded 2007Hard Tech

About Momotaro-Gene

Momotaro Gene is a clinical-stage biotherapeutics company specializing in the development of novel gene therapies aimed at treating cancer. The company is currently conducting a Phase 2 clinical trial at Baylor College of Medicine in Houston, Texas, to evaluate the efficacy, safety, and tolerability of its lead therapeutic candidate, MTG201, in combination with the PD-1 inhibitor nivolumab. This trial targets patients with relapsed malignant pleural mesothelioma who have not responded to standard platinum-based chemotherapy. The primary goal is to assess the treatment's efficacy in this patient group. Momotaro Gene has previously completed two Phase 1 trials of MTG201, which showed promising safety and tolerability in patients with malignant mesothelioma and localized prostate cancer. The company's business model focuses on advancing its gene therapy pipeline through clinical trials, with the potential to generate revenue through partnerships and licensing agreements. Momotaro Gene operates in the biopharmaceutical market, serving patients with aggressive cancers that have limited treatment options. The company's approach combines gene therapy with immunotherapy to explore synergistic anti-tumor effects, addressing a critical need for new treatment options in relapsed cancer forms.

Source: Dealroom company data

Momotaro-Gene in the Okayama ecosystem

Live from Dealroom

The Momotaro-Gene office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Nissay Capital
  • BiGEN
  • Kyorin Pharmaceutical

Series B and later2 investors entered at this stage

  • Nippon Venture Capital
  • Iyogin Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇯🇵 Japan · Okayama HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Momotaro-Gene on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Momotaro-Gene on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.